Gap IM-402: Test, optimize and validate pharmacological preventive/mitigative countermeasures.
Last Published:  11/23/20 11:55:10 AM (Central)
Responsible Element: Human Health Countermeasures (HHC)
Status: Open
Description
Present state of knowledge: At present, NASA does not have a validated countermeasure for spaceflight-associated immune system dysregulation. An international, multi-disciplinary group of experts was convened in 2018-2019 to discuss different aspects of a future immune countermeasure, and a specific candidate protocol was formulated and published in a pair of articles in the journal Frontiers. Several components of the proposed multi-pronged countermeasure are pharmacological in nature, including various pharmacological interventions such as antivirals, polyclonal IgG, or G-CSF/IL-2 based immune ‘boosters’. The antiviral option is the subject of a current study at McMurdo Station, Antarctica.
Research approach: Several HRP-funded efforts are underway or in planning phases. A rodent study is investigating IL-2 and zoledronic acid as potential countermeasures. A human analog-based study at the Antarctic McMurdo Station is investigating valacyclovir. A study is being planned to take place in the Antarctic Palmer Station that will evaluate an integrated immune countermeasure that may include antiviral or other pharmacological components.
Target for Closure
Validated pharmacological countermeasures for prevention/mitigation of immune dysfunction. 
Mappings
Risk Risk of Adverse Health Event Due to Altered Immune Response
You are here! Gap IM-402: Test, optimize and validate pharmacological preventive/mitigative countermeasures.
Active
Planned-Funded

Documentation:
No Documentation Available